Several banks consider Demant’s own expectations for the year to be too conservative.
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a financial analyst report with no clinical implications for audiology practice.
Demant's strong financial outlook signals continued investment capacity in hearing aid innovation, which may influence product pipelines and market competition for clinics and dispensers.
- 01Nordea raised its stock price target for Demant following a positive company outlook.
- 02Multiple banks suggest Demant's own annual guidance may be overly conservative.
- 03No clinical data, product launches, or practice-relevant findings are contained in this report.
- 04Demant is the parent company of major hearing brands including Oticon and Bernafon.
Demant's own annual expectations may be overly conservative according to several banks.
opinionunclearNordea raised its price target for Demant following a positive company outlook.
press releasesupported